JPRN-jRCT2071220111进行中（未招募）3 期
A Phase 3, Randomized, Active-controlled, Observer-blinded, Non-inferiority Study to Evaluate the Safety and Immunogenicity of Booster Immunization with DS-5670a/b (Bivalent: Original Strain/Omicron Strain BA.4-5) in Subjects Aged 12 Years and Older Who Have Completed Initial and Booster Immunization with SARS-CoV-2 Vaccines
Inoguchi Akihiro0 个研究点目标入组 1,400 人开始时间: 2023年2月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main Study:
- •1) Subjects aged 12 years and older at the time of informed consent.
- •2) Having provided written consent to study participation (by the subject or via his/her legal representative).
- •3) Having completed initial immunization with Comirnaty IM and booster immunization with Comirnaty RTU IM or having completed booster immunization with Comirnaty RTU IM after receiving initial and booster immunization with Comirnaty IM in the past, with at least 3 months elapsed since the last booster dose of Comirnaty RTU IM.
- •4) Able to comply with the rules of the study, undergo physical examinations and tests that are specified in the protocol, and report symptoms or other issues (reporting by the legal representative is also acceptable).
- •Sub Study A:
- •1) Subjects aged 12 years and older at the time of informed consent.
- •2) Having provided written consent to study participation (by the subject or via his/her legal representative).
- •3) Having completed initial and booster immunization with Comirnaty IM in the past, with at least 3 months elapsed since the last booster dose.
- •4) Able to comply with the rules of the study, undergo physical examinations and tests that are specified in the protocol, and report symptoms or other issues (reporting by the legal representative is also acceptable).
- •Sub Study B:
- •1) Subjects aged 12 years and older at the time of informed consent.
- •2) Having provided written consent to study participation (by the subject or via his/her legal representative).
- •3) Having completed initial immunization with approved SARS-CoV-2 vaccines (Comirnaty IM or Spikevax IM) and booster immunization with approved SARS-CoV-2 vaccines (Comirnaty IM, Comirnaty RTU IM [bivalent: original strain/Omicron strain BA.1, or bivalent: original strain/Omicron strain BA.4-5], Spikevax IM [univalent: original strain, bivalent: original strain/Omicron strain BA.1, or bivalent: original strain/Omicron strain BA.4-5], or Nuvaxovid IM) or DS-5670a in the past, with at least 3 months elapsed since the last booster dose.
- •4) Able to comply with the rules of the study, undergo physical examinations and tests that are specified in the protocol, and report symptoms or other issues (reporting by the legal representative is also acceptable).
排除标准
- •1) Having any serious cardiovascular, renal, hepatic, blood, neuropsychiatric, developmental disorder, thrombocytopenia, or coagulopathy.
- •2) Having a medical history of vaccination-related convulsions or epilepsy.
- •3) Having a concurrent or medical history of myocarditis or pericarditis.
- •4) Having tested positive in the past (in the case of Sub Study B, within 3 months before informed consent) for SARS-CoV-2 infection (based on RT-PCR, other nucleic acid detection methods, or SARS-CoV-2 antigen test), or having been diagnosed with COVID-19 based on a physician's examination.
- •5) Having been diagnosed with immunodeficiency in the past or having a close relative with congenital immunodeficiency.
- •6) Having symptoms suspected of SARS-CoV-2 infection (eg, respiratory symptoms, headache, malaise, anosmia, dysgeusia, pharyngeal pain) at the time of informed consent.
研究者
相似试验
进行中（未招募）
不适用
A clinical trial to determine if the investigational product MnB vaccine works the same every time a batch (or lot) of the vaccine is made.Bacterial MeningitisMedDRA version: 14.1Level: LLTClassification code 10028910Term: Neisseria meningitides meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-023873-20-ITPFIZER INC.3,752
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyEUCTR2009-015198-11-SEPfizer Inc, 235 East 42nd Street, New York, NY 100175,700
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyBacterial MeningitisMedDRA version: 17.1Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 100000004862EUCTR2009-015198-11-DEPfizer Inc, 235 East 42nd Street, New York, NY 100175,700
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyEUCTR2009-015198-11-Outside-EU/EEAPfizer Inc, 235 East 42nd Street, New York, NY 100175,700
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyEUCTR2009-015198-11-EEPfizer Inc, 235 East 42nd Street, New York, NY 100175,700